Research Analysts Offer Predictions for COGT FY2025 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Stock analysts at Leerink Partnrs increased their FY2025 earnings estimates for Cogent Biosciences in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the technology company will earn ($2.26) per share for the year, up from their previous estimate of ($2.41). The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ FY2026 earnings at ($1.17) EPS.

COGT has been the topic of a number of other research reports. Wedbush reissued a “neutral” rating and set a $11.00 price target on shares of Cogent Biosciences in a research report on Monday, January 13th. JPMorgan Chase & Co. increased their target price on Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Needham & Company LLC cut shares of Cogent Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Finally, HC Wainwright decreased their target price on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Cogent Biosciences Trading Up 0.2 %

Shares of COGT opened at $8.76 on Monday. Cogent Biosciences has a 12 month low of $5.37 and a 12 month high of $12.61. The firm’s 50 day moving average is $8.41 and its 200-day moving average is $9.68. The stock has a market capitalization of $967.65 million, a PE ratio of -3.53 and a beta of 1.77.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings data on Tuesday, November 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). During the same quarter in the previous year, the company earned ($0.64) EPS.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Barclays PLC increased its position in Cogent Biosciences by 124.8% during the 3rd quarter. Barclays PLC now owns 175,684 shares of the technology company’s stock worth $1,897,000 after purchasing an additional 97,541 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Cogent Biosciences by 20.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 825,793 shares of the technology company’s stock worth $8,919,000 after buying an additional 139,096 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Cogent Biosciences by 14.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,752 shares of the technology company’s stock valued at $301,000 after acquiring an additional 4,528 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cogent Biosciences by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,280,793 shares of the technology company’s stock valued at $24,638,000 after acquiring an additional 300,062 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Cogent Biosciences by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 171,999 shares of the technology company’s stock valued at $1,858,000 after acquiring an additional 44,287 shares in the last quarter.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.